Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

4.0%

1 terminated/withdrawn out of 25 trials

Success Rate

93.3%

+6.8% vs industry average

Late-Stage Pipeline

20%

5 trials in Phase 3/4

Results Transparency

0 of 14 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

6(46.2%)

Phase 3

4(30.8%)

Phase 2

2(15.4%)

Phase 4

1(7.7%)

13Total

N/A(6)

Phase 3(4)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (25)

Showing 20 of 25 trials

NCT05804032Phase 3Completed

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Role: lead

NCT03617731Phase 3Active Not Recruiting

Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

Role: lead

NCT06216158Phase 3Recruiting

Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

Role: lead

NCT05695508Phase 2Recruiting

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Role: lead

NCT05358314Completed

Investigating Neuronal and Peripheral Markers of Brain Heart Interaction in Healthy Participants Under Stress

Role: lead

NCT05313347Completed

Neural Correlates of Sensory Specific Satiety